The race to best treat a dis­ease long con­fused with MS heats up with Roche's PhI­II re­sults

6 years ago
R&D

An­a­lyst Bri­an Sko­r­ney goes griz­zly on Bio­gen’s Alzheimer’s ‘hype,’ ‘fear­mon­ger­ing’ and ‘sta­tis­ti­cal ...

6 years ago
R&D

Just days ahead of his big strate­gic re­veal, Sanofi CEO Paul Hud­son lines up a $350M sale

6 years ago
R&D

Shak­ing up Chi­na's PD-(L)1 re­im­burse­ment land­scape, In­novent, Eli Lil­ly earn cov­et­ed spot on na­tion­al cov­er­age

6 years ago
China
Pharma

As­traZeneca gains a speedy Imfinzi re­view in race to beat Roche on front­line SCLC

6 years ago
R&D

Bak­er Bros. places a $250M bet on a po­ten­tial ri­val to Re­gen­eron and No­var­tis — with a $1B-plus pay­off on the line

6 years ago
Deals

Nu­mero quat­tro: Im­munol­o­gy ex­perts at deal-fo­cused IFM line up $55.5M for the next leg of their drug ex­plo­ration ...

6 years ago
Financing

No­var­tis, Ver­tex out­line big gene ther­a­py plans — fu­el­ing a glob­al boom

6 years ago
Cell/Gene Tx

Mass Gen­er­al team presents mouse da­ta to back the case for us­ing re­for­mu­lat­ed asth­ma drug to treat ALS

6 years ago
Discovery

Biotech vet Paul Bren­nan takes helm at re­gen­er­a­tive med biotech; Ax­cel­la names CFO

6 years ago
Peer Review

In­sid­er ac­count of UCB’s $2.1B deal to buy Ra Phar­ma spot­lights a dis­ci­plined M&A strat­e­gy — and $120M wind­fall ...

6 years ago
R&D

Ko­re­an biotech’s shares soar for a 'best of ES­MO' award it nev­er re­ceived

6 years ago
R&D

J&J, Te­va and four oth­ers un­der crim­i­nal probe as feds in­ves­ti­gate opi­oid mak­ers for fail­ing to mon­i­tor dis­tri­b­u­tion

6 years ago
Pharma

FDA ap­proves 5 new cost­ly drugs well ahead of PDU­FA dates

6 years ago
Pharma
FDA+

Feds add fraud charges to the mul­ti­tude of ac­cu­sa­tions made against for­mer MiMedx ex­ecs

6 years ago
Pharma

Mer­ck adds an­oth­er OK to Keytru­da score­board; Arde­lyx, Ky­owa Kirin broad­ens part­ner­ship be­yond tena­panor

6 years ago
News Briefing

Roche's Xofluza may give rise to re­sis­tant strains, rais­ing fears of a 'worst case sce­nar­i­o'

6 years ago
R&D

With mo­men­tum from FDA OK, SK Bio­phar­ma to breath new life in­to Ko­re­an biotech with $850M IPO — re­port

6 years ago
Financing

An­oth­er can­cer vac­cine play out of Gene­va shoots for 'hard end­point' in PhII head and neck can­cer test

6 years ago
Financing

There’s one end­point that the boom­ing bio­phar­ma in­dus­try has failed at mis­er­ably: fi­nan­cial tox­i­c­i­ty

6 years ago
Bioregnum
R&D

Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

6 years ago
R&D

OPDP let­ter crit­i­cizes drug com­pa­ny for fail­ing to dis­close risk in­fo on­line

6 years ago
R&D

Velox­is wins $1.3B buy­out, and the new own­er plans to fol­low up with new deals

6 years ago
Deals

La Jol­la CEO de­camps just as biotech faces a reck­on­ing for iron over­load drug

6 years ago
R&D
First page Previous page 889890891892893894895 Next page Last page
A service from the Financial Times